v3.26.1
Condensed Condensed Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Liabilities, Current [Abstract]    
Accrued expenses $ 225 $ 659
TOTAL LIABILITIES 37,928 659
Commitments and Contingencies
SHAREHOLDERS' DEFICIT    
Additional paid-in capital 10 10
Accumulated deficit (37,928) (659)
Total Stockholder's Deficit (37,928) (659)
Archimedes Tech SPAC Partners II Co [Member]    
Current assets    
Cash 1,077,839 1,362,766
Prepaid expenses 140,921 111,403
Total current assets 1,218,760 1,474,169
Prepaid insurance   9,896
Demand deposit held in Trust Account 242,002,931 239,860,969
TOTAL ASSETS 243,221,691 241,345,034
Liabilities, Current [Abstract]    
Accrued expenses 305,087 61,277
Accrued offering costs   75,000
Due to related party 4,283 1,239
Total current liabilities   137,516
Deferred underwriting fee payable 8,050,000 8,050,000
TOTAL LIABILITIES 8,359,370 8,187,516
Commitments and Contingencies
Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.52 and $10.43 per share as of March 31, 2026 and December 31, 2025, respectively 242,002,931 239,860,969
SHAREHOLDERS' DEFICIT    
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
Ordinary shares, $0.0001 par value; 400,000,000 shares authorized; 6,590,000 shares issued and outstanding (excluding 23,000,000 shares subject to possible redemption) as of March 31, 2026 and December 31, 2025 659 659
Accumulated deficit (7,141,269) (6,704,110)
Total Stockholder's Deficit (7,140,610) (6,703,451)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT 243,221,691 241,345,034 [1]
Related Party [Member] | Archimedes Tech SPAC Partners II Co [Member]    
Liabilities, Current [Abstract]    
Due to related party 4,283 1,239
Accrued and other current liabilities $ 309,370 $ 137,516
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.